<?xml version="1.0" encoding="UTF-8"?>
<ref id="B86-pharmaceutics-10-00039">
 <label>86.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Giuliani</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Balducci</surname>
    <given-names>A.G.</given-names>
   </name>
   <name>
    <surname>Zironi</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Colombo</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Bortolotti</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Lorenzini</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Galligioni</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Pagliuca</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Scagliarini</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Calz√†</surname>
    <given-names>L.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates</article-title>
  <source>Drug Deliv.</source>
  <year>2018</year>
  <volume>25</volume>
  <fpage>376</fpage>
  <lpage>387</lpage>
  <pub-id pub-id-type="doi">10.1080/10717544.2018.1428242</pub-id>
  <?supplied-pmid 29382237?>
  <pub-id pub-id-type="pmid">29382237</pub-id>
 </element-citation>
</ref>
